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Abstract
Pregnancy is an altered physiological state where an 
organism essentially foreign to the individual carrying it, grows, 
develops and at an appropriate time probably initiates a series 
of signals which lead to its safe expulsion from the woman’s 
body.
The immunological changes which allow this process are 
unique to pregnancy.  Recent work in this field has led to a 
further understanding of the changes which operate to adapt 
the woman to the pregnant state.
The concept that has developed over the years is one 
where a number of factors exert their effect both at the 
systemic but mostly at the local uterine level to modulate the 
immune response which will then refrain from mounting an 
inflammatory response against the invading trophoblast.  The 
main protagonists of this immunomodulation are embryonic 
factors, uterine (endometrial) NK cells and, of course, the 
hormone progesterone.
Progress has been made from the original observations 
of miscarriage rates in HLA sharing couples and with the 
possibility of research in couples undergoing IVF cycles, 
factors are being identified which initiate immunomodulation. 
Once implantation occurs the endometrial NK cells which are 
abundant from the late luteal phase are activated to control 
trophoblastic invasion and enhance the changes in blood vessels 
which allow for adequate feto-maternal perfusion.
The immune response is controlled by PIBF under the 
influence of progesterone to bias towards a humoral response 
and suppress a cytotoxic response.  All these processes are 
prone to fail at times and the clinical manifestation of such a 
failure is miscarriage along with other obstetric complications 
such as intra-uterine growth retardation, pre-eclampsia and 
placental abruption.
Progress in the understanding of the immunological 
processes which protect pregnancy will  help in elucidating  the 
mechanisms whereby these processes fail.
A consequence of this should be the explanation of those 
cases as yet classified as unexplained recurrent miscarriage.
The literature indicates that the prognosis for this group 
of patients is not as encouraging as one would hope and that 
progress in this area  is eagerly awaited by both patients and 
doctors working in this field.
Introduction
The establishment of a mammalian pregnancy is a significant 
development over lower vertebrates.  The long gestation period 
ensures the birth of a well developed neonate who is born 
with a mother at hand and who immediately assumes further 
responsibility, feeding and nurturing the newborn to ensure it 
reaches adult life and reproductive potential.
This is in stark contrast to what happens in lower vertebrates 
where a large number of eggs are hatched so that few may 
survive to adulthood given the large loss of life during the early 
phase of life. Mammalian pregnancies are internalised, i.e. grow 
inside a uterus and require the exchange of substances across 
the placento-uterine interface.
This is where the achievement essentially lies.1  The 
hemochorial placenta found in humans (and mice) is associated 
with intimate interaction between the conceptus and the uterus. 
Given that the human embryo expresses its genomic features as 
early as the 2-cell stage, how does the embryo survive maternal 
immune surveillance?
Initially a mechanical protection is provided by the zona 
pellucida and a few layers of cells from the cumulus ophorus. 
This protects it during its journey from the ampullary end of 
the fallopian tube to the uterine cavity which takes between 2 
to 5 days. 
Once the embryo comes into contact with the endometrium, 
the maternal immune system is in a position to set in motion a 
host vs graft reaction which should result in the destruction of 
the embryo and the resultant clinical event - miscarriage.
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Immunotolerance 
and successful implantation
In 1988 the concept that genetic similarity (HLA sharing) 
between the parents leads to a lack of maternal recognition and 
eventual miscarriage became popular.2  It is however clear, that 
pregnancy is not a classical graft/host reaction as in a transplant 
but involves specific compounds derived from the conceptus and 
which modulate the immune response.
The occurrence of term abdominal pregnancies strongly 
suggests that maternal immuno-modulation is a systemic one 
and not localised to the uterus.
Also, the success rates of egg donation programmes 
indicates that sharing of materno-foetal genes is not necessary 
and favours the idea that embryo-derived signals initiate the 
protection process.3  It is also a fact that these same egg donation 
programmes are associated with a high incidence of pregnancy 
complications especially pre-eclampsia and intra-uterine growth 
restriction which indicates that gene sharing may result in more 
efficient immunotolerance and is therefore less likely to be 
associated with complications.4
Further evidence of an embryonic role in successful 
pregnancies is that defective pregnancies are rejected 
(miscarried) early – probably reflecting a sub-optimal or actual 
failure of the mechanisms that lead to immuno-tolerance.
A low-molecular weight peptide present only in pregnancy 
and in all mammalian species has been identified and has 
been designated Pre-implantation factor (PIF).  It is an 
embryo derived factor5 and seems to fit the role of a primary 
immuno-modulator which is present very early on, even before 
implantation, paving the way for a successful pregnancy.
Its presence is detected as early as fertilization i.e. before 
implantation.  Its role has been studied by following a series of 
pregnancies after embryo transfer in IVF cycles and the presence 
of PIF activity in maternal sera has been reported to predict 
viable pregnancy with excellent sensitivity (88%), specificity 
(95%), and positive and negative predictive values (94% and 
90% respectively).6  These results are strongly suggestive that 
PIF is essential for initiating maternal immuno-modulation 
(not suppression) and possibly to prime the endometrium and 
prepare it for implantation.
Uterine Natural Killer cells
The endometrium undergoes decidual change in the 
late luteal phase of the menstrual cycle.  The dominant cell 
population in the decidua in the first trimester of pregnancy 
are Natural Killer (NK) cells.
There is evidence that, as the blastocyst implants, uterine NK 
cells become activated and through a series of molecules control 
cytotrophoblastic invasion through their cytotoxic activity and 
also initiate changes in the decidual arteries to increase the blood 
supply to the foetoplacental unit.7
Also through Th2 type cytokine expression (vide infra) and 
growth factors, NK cells  participate in placental aggregation 
and local immunosuppression and modulation.8,9
Figure 1:  Trophoblat does not express HLA-A or B but cells of innate immunity have receptors to recognize trophoblast 
HLA ligands. Cytokine milieu favors implantation with litte evidence of inflammation, adoptive immunity or cytokoxicity
Secretion of immuno-supptessive Cytokines Reproduced from ‘Critchley H, Cameron I, Smith S 
editors.  Implantation and Early Development. 
RCOG Pres 2005, with permission of the Royal 
College of Obstercians and Gynaecologists.
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Decidual NK cells are also the main cell population involved 
in alloimmune miscarriage10 and the classical T and B cells of 
the adaptive immune system are sparse in these circumstances. 
Under the influence of Th1 cytokines (unfavourable for 
pregnancy) they become classical NK cells expressing CD16 
which can damage the trophoblast either directly through 
cytolytic activity or indirectly by producing inflammatory 
cytokines.11
NK cell activity seems to be especially important in achieving 
an optimal balanced trophoblast invasion.  This means neither 
underinvasion resulting in underperfusion of the spiral 
arterioles which is the model for IUGR and pre-eclampsia14 nor 
overinvasion leading to morbid adherence of the placenta.
This control is achieved through foetal polymorphic HLA-
C genes which are expressed by the trophoblast cells and 
modulated through the Killer Immunomodulating Receptors 
(KIR) found on NK cells.15  Trophoblasts do not express HLA-A 
or B genes (see Figure I).
Clinical studies have shown that patients who tend to abort 
have increased numbers of NK cells in the uterus as well as 
increased blood NK cell subsets and antibodies all of which have 
been associated with the miscarriage of a euploid (therefore 
presumably normal) embryo.
This knowledge led to an attempt to assess the risk of 
miscarriage using a serum assay of the level of NK cell activity 
and selecting women for immunotherapy (e.g. prednisolone) in 
those cases who exhibit a high level of NK cell activity.12,13
Unfortuantely a major flaw in this reasoning is that the NK 
cells in the decidua are a totally different cell populations from 
those measured in peripheral blood.  
The association is therefore very tenuous, and this practice 
has largely been abandoned.
Progesterone
Progesterone is the hormone of pregnancy 
Inadequate levels of progesterone in early pregnancy will 
unequivocally lead to miscarriage.16  Recently this hormone 
has received considerable attention as it has been shown to 
be effective in preventing preterm labour.17  However, its role 
in preventing miscarriage has been bedevilled by contrasting 
results when it comes to achieving statistically significant 
outcomes.18
Breakthroughs in the way progesterone modulates the 
immune response have confirmed its essential and central 
function in maintaining pregnancy and re-inforced the belief 
workers in the field of miscarriage have had in progesterone 
supplementation.
Progesterone Induced Blocking Factor (PIBF)
PIBF is a 34 kDa protein that can block NK cell-mediated 
lysis of K562 tumour cells.19  The expression of this protein 
by CD8 T lymphocytes (gamma/delta T cells) requires 
progesterone for expression, and it has therefore been called 
progesterone induced blocking factor.  PIBF is only synthesised 
at the maternal-foetal interface because  that is where there 
is an adequate progesterone concentration to stimulate this 
synthesis.
When there are sufficient levels of endogenous progesterone 
to form PIBF, this then safeguards the foetus by preventing 
inflammatory and thrombotic secondary reactions towards the 
trophoblast through three distinct actions20 :
 • by inducing asymmetric, protective ‘blocking’ antibodies21
• by blocking NK cell degranulation22
• by inducing T-helper 2 (Th2) cell dependent cytokines, 
thereby shifting the balance towards a Th2-dominated, 
cytoprotective immune response.23
The diagram (Figure 2) illustrates clearly the crucial role 
of progesterone through PIBF in the process of successful 
implantation and development of trophoblast and therefore 
the foeto-placental unit.
Progesterone receptors (PgR) have not been demonstrated 
in normal T-lymophocytes but are found in gamma/delta T 
lymphocytes and the high concentration of progesterone in 
the maternal-foetal interface induces the expression of PIBF 
which can then exert its influence on immunomodulation of 
pregnancy exactly at the foeto-maternal interface where it is 
most important.  It is interesting to note that liver transplants, 
blood transfusions and paternal lymphocyte injections in the late 
Figure 2: The effect of PIPF on T-helper cell bias
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luteal phase increases PIBF expression in women.24  Much less 
PIBF expression has been reported in women who miscarried 
compared to women who carried their pregnancy to term.25,26
The difficulty in determining the role of progesterone in 
preventing recurrent pregnancy loss is due to the difficulty in 
determining who has progesterone deficiency.  Luteal phase 
serum assays and endometrial biopsies lack both sensitivity 
and specificity.
Check27 argues that “if the need for extra progesterone 
supplementation occurred in only one-third of pregnancies, 
would it not be worthwhile to use such supplementation in every 
cycle to eliminate a 33% miscarriage rate.”
Two studies28,29 have shown that pregnancies presenting with 
low levels of progesterone (8 and 15ng/ml) could be salvaged 
with aggressive progesterone therapy.  However, many of the 
studies on progesterone therapy in recurrent miscarriage which 
have been carried out, are small, lacked placebo controls or 
were not double-blinded.  This fact is the view held by Professor 
Regan30 of the St Mary’s group who argues that since it is not 
evidence-based practice, it should not be used routinely although 
it not associated with any foetal adverse effects.
Historical correlations
Unexplained recurrent miscarriage deserves special mention 
as this represents a particularly distressing aspect of the 
condition for both patients and physicians alike.
Attempts have been made in the past to classify these cases 
as immunological in nature.  This was particularly so when 
the antiphospholipid antibody syndrome (APS)31 was first 
described.
The enthusiasm was such that Pattison et al.32 postulated 
at the time that other antiphopholipid antibodies (apart from 
lupus anticoagulant and anticardiolipin antibodies) may be 
responsible for unexplained recurrent miscarriage.  In fact, 
approximately 30% of women with ‘unexplained recurrent 
miscarriage’ have increased serum levels of autoantibodies, 
especially antiphosholipid antibodies.33 
This observation had in fact, led to the definition of 
Reproductive Autoimmune Failure Syndrome (RAFS) already 
in 1988.34  Later in 1999 the American Society of Reproductive 
Immunology, defined Reproductive Autoimmune Syndrome 
(RAS) as including not only RAFS but also APS (antiphospholipid 
syndrome).35,36  This approach was advocated as both drugs are 
very safe to use in pregnancy and have shown a significant 
benefit in the presence of antiphospholipid antibodies.37,38,39  
The development of an immunological aspect to the aetiology 
of recurrent miscarriage was reflected in the recommended 
pharmacological treatment of the time, from corticosteroids 
to immunoglobulins, paternal lymphocyte transfusions and 
subsequently a combination of heparin and aspirin.
In 1996 and 1997 Kutteh37 and Rai et al.38  published their 
studies confirming that a combination of heparin and aspirin 
was superior to prednisolone and aspirin and to all the other 
therapies attempted i.e. warfarin, azathiaprine, plasmapheresis 
and intravenous immunoglobulin in the management 
of recurrent miscarriage associated with the presence of 
antiphospholipid antibodies.  Also by then Cauchi et al.40 had 
published their study concluding that there was no benefit 
from paternal lymphocyte infusion in recurrent miscarriage, a 
treatment based on the concept of immunotolerance and made 
popular following the original publication by Mowbray et al.41
Heparin, used clinically as an anticoagulant, also has anti-
inflammatory properties and has been described to inhibit 
interferon-gamma (IFN-gamma) responses in endothelial cells. 
It has also been shown to be capable of binding to aPL and also 
of antagonising the action of Th1 cyromine IFN-gamma, thereby 
protecting the trophoblast and maternal vascular endothelium 
from damage in early pregnancy.42
A number of papers have reported the effect of heparin on 
chemokines and Th1 cells.  This has confirmed heparin to have 
anti-inflammatory properties rather than simply anti-coagulant 
ones.43  An important fact which explains the role of heparin is 
the first trimester of pregnancy when there is no effective foeto-
maternal circulation, but when if omitted in APS patients will 
lead to a high incidence of miscarriage.  In fact, if one looks at 
the results of the Rai38 study it becomes clear that the survival 
is not affected when treatment is started after the 13th week of 
gestation, suggesting that the effect of heparin and aspirin is 
mainly during the first trimester i.e. during the development of 
the placento-uterine circulation.  This new feature of heparin 
is leading investigators to consider aspirin as being possibly 
unnecessary in the treatment of antibody-positive recurrent 
miscarriage, but because of the results achieved with aspirin in 
some early studies, it may be difficult to design studies without 
it altogether. Certainly as the molecular biology of recurrent 
miscarriage becomes more clear and the actions of known 
therapeutic agents on these molecules unravel, the possibility 
that unexplained recurrent miscarriage and its empirical 
treatment will become a thing of the past is a possibility.  This 
will be very welcome to us physicians but especially to our 
patients who are at a loss to believe that they have suffered three 
pregnancy losses while no cause can be found.
The renaissance of progesterone following the important 
breakthroughs in the processes of immunomodulation coupled 
by years of clinical application and the knowledge of its safety 
(10.3 million babies exposed to dydrogesterone worldwide44) 
lead me to ask IF we should be prescribing progesterone to all 
women who are trying to conceive?  Not evidence based but 
there is a sound scientific basis to this idea.
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